A proposed new federal law could provide some competitive guardrails for the company's most important product.

Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...

Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Novo Nordisk says it is taking a flexible portfolio approach and plans to price the injectable semaglutide close to Wegovy’s ...

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...

Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...

Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving ...

Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and ...